Figure 4.

Analysis of Vaccine Effectiveness against B16/Ova Tumor

(A) Prophylactic 663-optOva vaccination gives protection against metastatic tumor spread. B16/Ova metastatic nodules are visible as black dots. Vaccinated mice had 0–13 B16/Ova nodules on the lungs. Non-vaccinated mice all had more than 200 B16/Ova nodules on lungs, so all values were marked as 200 for the purpose of this graph (right panel). Left panel: images of lungs. **p < 0.01. (B) Growth of intradermal B16/Ova tumor implanted on mouse flanks 2 weeks after vaccination. Statistical differences between groups were assessed by one-way ANOVA, vaccinated versus non-immunized. *p < 0.05; **p < 0.01; ns, non-significant. (C) Kaplan-Meyer survival plots of animals depicted in (B). (D) Post-necroptic analysis of Ova expression in tumor by western blotting on day 25 after tumor implantation.